
Brainsway Ltd. BWAY
$ 19.11
0.47%
Annual report 2024
added 12-27-2025
Brainsway Ltd. General and Administrative Expenses 2011-2026 | BWAY
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Brainsway Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 5.78 M | 3.31 M | 4.39 M | 8.23 M | 7.47 M | 5.74 M | 3.61 M | 2.34 M | 1.43 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 8.23 M | 1.43 M | 4.7 M |
General and Administrative Expenses of other stocks in the Diagnostics research industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Akumin
AKU
|
2.08 M | - | -17.87 % | $ 25.9 M | ||
|
Centogene N.V.
CNTG
|
46.7 M | - | -6.23 % | $ 30.6 M | ||
|
Accelerate Diagnostics
AXDX
|
39.2 M | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
16.1 M | - | -13.05 % | $ 7.29 M | ||
|
Co-Diagnostics
CODX
|
14.3 M | $ 5.31 | 4.89 % | $ 156 M | ||
|
Burning Rock Biotech Limited
BNR
|
490 M | $ 20.49 | -2.36 % | $ 215 M | ||
|
Castle Biosciences
CSTL
|
200 M | $ 38.74 | -0.41 % | $ 1.08 B | ||
|
Chembio Diagnostics
CEMI
|
24.3 M | - | 0.22 % | $ 16.8 M | ||
|
Danaher Corporation
DHR
|
7.76 B | $ 228.43 | -0.21 % | $ 167 B | ||
|
DexCom
DXCM
|
1.19 B | $ 66.86 | 0.74 % | $ 25.8 B | ||
|
BioNano Genomics
BNGO
|
51.9 M | $ 1.56 | 1.96 % | $ 1.98 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
22.3 M | - | - | $ 562 M | ||
|
Enzo Biochem
ENZ
|
21.7 M | - | -8.98 % | $ 14.8 K | ||
|
DermTech
DMTK
|
43.8 M | - | -11.32 % | $ 2.94 M | ||
|
DarioHealth Corp.
DRIO
|
18.1 M | $ 11.42 | 0.35 % | $ 324 M | ||
|
IQVIA Holdings
IQV
|
1.99 B | $ 225.43 | 0.01 % | $ 40.9 B | ||
|
Exact Sciences Corporation
EXAS
|
191 M | $ 101.79 | 0.23 % | $ 18.9 B | ||
|
Fulgent Genetics
FLGT
|
88.1 M | $ 25.95 | -1.24 % | $ 785 M | ||
|
Global Cord Blood Corporation
CO
|
187 M | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
97.9 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
3.83 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
126 M | - | 0.12 % | $ 80.1 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
453 M | - | - | $ 10.7 B | ||
|
Heska Corporation
HSKA
|
64.1 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
15.8 M | - | -20.0 % | $ 1.06 M | ||
|
CareDx, Inc
CDNA
|
118 M | $ 19.2 | 1.91 % | $ 1.03 B | ||
|
Celcuity
CELC
|
9.06 M | $ 100.08 | 0.34 % | $ 3.95 B | ||
|
Anixa Biosciences
ANIX
|
7.44 M | $ 3.09 | -0.96 % | $ 98.6 K | ||
|
Myriad Genetics
MYGN
|
276 M | $ 6.22 | 1.14 % | $ 564 M | ||
|
ENDRA Life Sciences
NDRA
|
7.06 M | $ 4.26 | -5.96 % | $ 2.29 M | ||
|
NeoGenomics
NEO
|
260 M | $ 11.76 | - | $ 1.49 B | ||
|
Guardant Health
GH
|
180 M | $ 101.08 | -1.04 % | $ 12.4 B | ||
|
National Research Corporation
NRC
|
46.6 M | $ 18.42 | -1.89 % | $ 452 M | ||
|
Aspira Women's Health
AWH
|
16.2 M | - | -6.19 % | $ 10.5 M | ||
|
OPKO Health
OPK
|
304 M | $ 1.26 | 0.4 % | $ 874 M | ||
|
Precipio
PRPO
|
9.45 M | $ 24.92 | 8.46 % | $ 32.3 M | ||
|
Personalis
PSNL
|
46.2 M | $ 7.76 | -2.52 % | $ 460 M | ||
|
Motus GI Holdings
MOTS
|
6.58 M | - | -34.28 % | $ 263 K | ||
|
Illumina
ILMN
|
1.09 B | $ 132.27 | 0.85 % | $ 21 B | ||
|
Charles River Laboratories International
CRL
|
751 M | $ 200.24 | 0.38 % | $ 10.3 B | ||
|
Quest Diagnostics Incorporated
DGX
|
1.77 B | $ 172.79 | -0.43 % | $ 19.2 B | ||
|
Biodesix
BDSX
|
80.5 M | $ 6.84 | 0.51 % | $ 887 M | ||
|
Koninklijke Philips N.V.
PHG
|
599 M | $ 27.14 | 0.22 % | $ 20 B | ||
|
Laboratory Corporation of America Holdings
LH
|
2.23 B | $ 250.12 | -0.3 % | $ 21 B | ||
|
ICON Public Limited Company
ICLR
|
585 M | $ 186.86 | 2.55 % | $ 15.4 B | ||
|
IDEXX Laboratories
IDXX
|
442 M | $ 666.09 | -1.54 % | $ 54.9 B | ||
|
Lantheus Holdings
LNTH
|
194 M | $ 66.89 | 0.51 % | $ 4.63 B | ||
|
Mettler-Toledo International
MTD
|
936 M | $ 1 395.51 | 0.09 % | $ 29.6 B | ||
|
Agilent Technologies
A
|
1.62 B | $ 136.02 | -0.04 % | $ 41.4 B |